- Telehealth Visits
- Insurance plan information
Athena Angelopoulos, MS
She | Her | HersGenetic Counselor • Cardiovascular Genetics- Telehealth Visits
- Insurance plan information
Athena Angelopoulos, MS
She | Her | HersGenetic Counselor • Cardiovascular Genetics- Telehealth Visits
- Insurance plan information
On this page
About me
Athena Angelopoulos is a genetic counselor who specializes in inherited cardiovascular disease.
Angelopoulos earned her master's degree in human genetics and genetic counseling at Stanford University.
Education & training
Board certification
- Certified Genetic Counselor, American Board of Genetic Counseling
Degree
- MS, Stanford University School of Medicine
My expertise
Specialties
- Genetic Counselor
- Cardiovascular Genetics
Component Name: Provider Research Listing component built but no clinical trials or publications to display
Clinical Trials query: q=health_gateway_id_ss%3A%28%223063%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%223063%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.